Experience

OmniAb, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Sr. Research Scientist

  • Nov 2022 - Present



Ligand Pharmaceuticals

• United States
• Biotechnology Research
• 1 - 100 Employee

• Sr. Research Scientist

  • Sep 2022 - Nov 2022



Metagenomi

• United States
• Biotechnology Research
• 100 - 200 Employee

• Scientist

  • Jun 2020 - Sep 2022



Boehringer Ingelheim

• Germany
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Scientist III

  • May 2019 - Jun 2020

  Position within the Process Analytics team. I applied HPLC-based methods to quantify molecular aggregates, charge variants, and patterns of glycosylation of monoclonal antibody therapies. Routinely evaluated impurities in antibodies undergoing downstream purification using ELISA- and qPCR-based assays. Position within the Process Analytics team. I applied HPLC-based methods to quantify molecular aggregates, charge variants, and patterns of glycosylation of monoclonal antibody therapies. Routinely evaluated impurities in antibodies undergoing downstream purification using ELISA- and qPCR-based assays.



University of California, Berkeley

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Scholar

  • Oct 2015 - Mar 2019

  Postdoctoral research in the laboratory of Eva Harris. Research projects focused on: - Evaluating cellular and humoral responses induced dengue virus (DENV) nonstructural protein 1 and cyclic dinucleotide adjuvants. - Characterizing DENV pathogenesis in vivo using rodent models of infection - In depth characterization of monoclonal and polyclonal antibodies against DENV and Zika virus NS1 Postdoctoral research in the laboratory of Eva Harris. Research projects focused on: - Evaluating cellular and humoral responses induced dengue virus (DENV) nonstructural protein 1 and cyclic dinucleotide adjuvants. - Characterizing DENV pathogenesis in vivo using rodent models of infection - In depth characterization of monoclonal and polyclonal antibodies against DENV and Zika virus NS1



PaxVax, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientific Consultant

  • Mar 2018 - Dec 2018

  Provided scientific and technical expertise to teams working on characterizing vaccine-induced responses against flaviviruses. Provided scientific and technical expertise to teams working on characterizing vaccine-induced responses against flaviviruses.